Open access
32,518
Views
28
CrossRef citations to date
0
Altmetric
Research Articles
Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial
David Adamsa Neurology Department, CHU Bicêtre, APHP, Université Paris-Saclay, Le Kremlin Bicêtre Cedex, FranceCorrespondence[email protected]
https://orcid.org/0000-0002-8722-4108View further author information
Ivailo L. Tournevb Department of Neurology, Clinic of Nervous Diseases, University Hospital Aleksandrovska, Medical University, Sofia, Bulgaria;c Department of Cognitive Sciences, New Bulgarian University, Sofia, BulgariaView further author information
, Mark S. Taylord Department of Clinical Immunology and Allergy, Westmead Hospital and Westmead Clinical School, University of Sydney, Sydney, NSW, Australia
https://orcid.org/0000-0003-1270-7209View further author information
Teresa Coelhoe Hospital de Santo António, Centro Hospitalar Universitário do Porto, Porto, PortugalView further author information
, Violaine Planté-Bordeneuvef Neurology – Amyloid Network, CHU Henri Mondor, APHP, University Paris Est – Créteil, Créteil, France
https://orcid.org/0000-0002-7880-2316View further author information
John L. Berkg Boston Medical Center, Boston University, Boston, Massachusetts, USA
https://orcid.org/0000-0002-1768-2373View further author information
Alejandra González-Duarteh Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México, D.F., México
https://orcid.org/0000-0002-2434-9560View further author information
Julian D. Gillmorei National Amyloidosis Centre, University College London, Royal Free Hospital, London, UK
https://orcid.org/0000-0001-6174-9232View further author information
Soon-Chai Lowj Department of Medicine, Division of Neurology, University Malaya Medical Centre, Kuala Lumpur, Malaysia
https://orcid.org/0000-0003-2392-6570View further author information
Yoshiki Sekijimak Department of Medicine (Neurology & Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan
https://orcid.org/0000-0002-8132-2743View further author information
Laura Obicil Amyloidosis Research and Treatment Centre, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy
https://orcid.org/0000-0001-7468-700XView further author information
Chongshu Chenm Alnylam Pharmaceuticals, Cambridge, Massachusetts, USAView further author information
, Prajakta Badrim Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA
https://orcid.org/0000-0003-1248-616XView further author information
Seth M. Arumm Alnylam Pharmaceuticals, Cambridge, Massachusetts, USAView further author information
, John Vestm Alnylam Pharmaceuticals, Cambridge, Massachusetts, USAView further author information
, Michael Polydefkisn Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
https://orcid.org/0000-0002-7584-7447View further author information
Pages 18-26
|
Received 28 Feb 2022, Accepted 16 Jun 2022, Published online: 23 Jul 2022
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.